Cabaletta Bio Inc (CABA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.47-0.29%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CABA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
CABA — litigation filed
Dated 2026-06-03
Other Events. On June 3, 2026, the Company posted to the “Investors & Media” section of the Company’s website at www.cabalettabio.com an updated corporate presentation (the “Corporate Presentation”). A copy of the Corporate Presentation is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference. On June 3, 2026, the Company issued the Press Release announcing new rese-cel data and development updates across the Company's autoimmune portfolio, in…
Why it matters: Finishing dosing is a key step for the BLA submission for myositis. It shows progress in development.
Supportive ifDosing for the 17-patient myositis trial group is now complete.
Worry ifDosing is late or not finished, which may mean problems in the trial.
Why it matters: New partnerships can help growth and support Cabaletta's plans.
Supportive ifA press release will announce a new partnership with a well-known biotech or pharma.
Worry ifNo new partnerships in the next quarter may show slow growth.
Why it matters: Rising costs can mean financial problems. Lower costs can help the outlook.
Worry ifOperating costs go down compared to past quarters.
Less concerning ifOperating costs are rising again. This will hurt the financial outlook.
Why it matters: This data will help check how well rese-cel treats systemic lupus erythematosus. Strong results could boost investor trust.
Supportive ifComplete Phase 1/2 cohort data from RESET-SLE is presented at the EULAR 2026 Congress.
Worry ifData presentation is delayed or results are not good.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$251 on $10,000 · ±2.5% | How much price usually moves either way. |
| Bad day | $756 loss on $10,000 · 7.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,349 loss on $10,000 · 43.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Expanding outpatient dosing could help more patients get treatment. No progress may show problems.
Watch forCabaletta says outpatient dosing is working well in ongoing trials.
Also watch forNo updates or setbacks in outpatient dosing plans are reported.
Why it matters: Progress on rese-cel is key for Cabaletta's growth. Delays or setbacks could hurt investor confidence.
Watch forA press release will share good trial results or new partnerships for rese-cel.
Also watch forAn announcement of delays or bad trial results for rese-cel.
Why it matters: The lawsuit's result could affect how the company works and its image.
Worry ifA press release about a good ruling or settlement in the lawsuit.
Less concerning ifA press release about a bad ruling or more legal issues.
Why it matters: Updates on trial designs can show progress toward BLA submissions. This matters for investor trust.
Supportive ifUpdates on trial designs for RESET-SSc will be shared in 1H26.
Worry ifNo updates are shared, which may mean delays or problems in trial design.
Why it matters: Long-term data will show how well rese-cel works over time. This is important for the BLA submission.
Supportive ifLong-term data from RESET-PV and RESET-SLE groups will come in 2H26.
Worry ifLong-term data shows no better results or worse results in patients treated with rese-cel.
Why it matters: Updates on these groups could show how well rese-cel works without preconditioning. This may affect future trials.
Watch forGood results from PC-free groups show improved clinical outcomes.
Also watch forResults from PC-free groups show no big improvement in clinical outcomes.
Why it matters: This data could prove rese-cel works well without preconditioning. It may change treatment methods.
Watch forData shows strong responses in patients. These patients were treated with PC-free rese-cel.
Also watch forData shows minimal or no clinical responses in PC-free cohorts.
Why it matters: Higher expenses may mean financial problems and future funding needs.
Worry ifOperating expenses rise beyond the current $44.3M loss.
Less concerning ifIf operating costs fall or stay the same, it shows better cost control.
Why it matters: High operating costs can mean money problems. This can hurt growth plans.
Worry ifOperating costs are higher than expected for the next quarter.
Less concerning ifOperating costs stay within or below the expected range.
Why it matters: Keeping expenses in check is key for financial health. Rising costs can show bigger problems.
Worry ifOperating expenses stay the same or go down. This is better than past quarters.
Less concerning ifOperating expenses go up more than expected. This leads to bigger financial losses.
Why it matters: New partnerships can boost growth and resources. Lack of partnerships may signal challenges.
Supportive ifLook for announcements of new partnerships that help growth.
Worry ifNo new partnerships announced in the next quarter.
Why it matters: This data is key for the first BLA submission for rese-cel. Positive results could support a strong regulatory pathway.
Supportive ifData from the RESET-Myositis trial shows that at least 80% of patients met the main goal.
Worry ifData shows less than 80% of patients meeting the primary endpoint.
Why it matters: Starting this trial is important for the rese-cel program. It may lead to more filings.
Supportive ifThe RESET-SSc trial starts with about 25 patients enrolled as planned.
Worry ifRESET-SSc trial does not initiate in 4Q26 as expected.
Why it matters: More outpatient dosing could help more patients get treatment. Good news may improve market views.
Supportive ifManagement says outpatient dosing is now part of ongoing trials.
Worry ifNo news or problems reported about outpatient dosing in the trials.